Abrocitinib is an oral, once‐daily, Janus kinase 1 (JAK1)‐selective inhibitor approved for the treatment of adults11, 12, 13, 14 and adolescents11, 12, 13 with moderate‐to‐severe AD. This evidence concerns the gene JAK1 and Alzheimer disease.